Comparison of 18-FDG SUV Value with Bone Scintigraphy Findings in Diagnosed Cases of Malignancy with Sclerotic Bony Metastasis
Objective: To determine the correlation of 18F-FDG SUV value with bone scintigraphy findings, i.e. uptake of Tc-99m in diagnosed cases of malignancy with sclerotic bone metastasis.
Study Design: Prospective longitudinal study.
Place and Duration of Study: Armed Forces Institute of Radiology and Imaging, Rawalpindi Pakistan, from Sep 2020 to Mar 2021.
Methodology: This study included 30 patients of age 18 to 80 years who had sclerotic bone metastasis as confirmed in histopathology. All patients underwent whole-body PET/CT scanning to evaluate sclerotic bone metastasis and determined 18-FDG SUV after 5MBq/kg body weight of 18-FDG was injected. After two weeks of PET/CT scan, Tc-99m bone scintigraphy was carried out, and SUV of Tc-99m was determined after 20-25mCi technetium-99 methylene disphosphonate was injected, and the correlation was assessed between SUV of 18-FDG and Tc-99m.
Results: The mean 18-FDG SUVmax and mean Tc-99m SUVmax, were, 21.31±8.77g/ml and 15.29±6.49g/ml respectively.21(70%) lesions on 18-FDG PET/CT and 8(26.7%) on Tc-99m bone scintigraphy were metastatic in bones. 18-FDG SUV on PET/CET and Tc-99m SUV on bone scintigraphy correlated positively with each other, and this correlation was found to be statistically significant (r=0.491, p=0.006).
Conclusion: 18-FDG SUV PET/CT significantly correlated with Tc-99m SUV on bone scintigraphy and helped detect metastatic lesions earlier and modulate treatment response.
Keywords: Bone metastasis, Bone scintigraphy, 18-FDG PET/CT, Tc-99m SUV.